Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?

Rafael Fonseca • 1 Jun 2018
ASCO 2018
Multiple Myeloma bb2121 CAR-T
CRB-401

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the exciting preliminary results of the CRB-401 trial (NCT02658929) investigating the efficacy and safety of anti-BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma (MM). Dr Fonesca discusses the trial in terms of response rates and measurable residual disease (MRD) status, and poses that these results are likely to translate well into progression-free and overall survival.

More from Rafael Fonseca

0:57
Optimal sequencing of therapies for transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Dec 2023
1:04
The value of MRD in transplant-ineligible patients with multiple myeloma
Rafael Fonseca • 9 Jan 2024
2:10
DRd versus VRd in patients with MM: a real-world retrospective analysis
Rafael Fonseca • 9 Dec 2023
1:52
Secondary cytogenetic abnormalities in MM: prognostic value of chromosome 1q gain vs amplification
Rafael Fonseca • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals